FDA Approval Insights: Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced Endometrial Cancer

Dr Mirza discusses the FDA approval of dostarlimab plus chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer; key efficacy and safety findings from the RUBY trial, and ongoing research investigating the role of frontline immune checkpoint inhibitors in patients with endometrial cancer.